TAP1 and neoplasm: As demonstrated in studies with a pharmacological inhibitor and TAP1 knockout MDA-MB-231 cells treated with inCT†CMVp480–516, a TEDbody delivers MHC-I-restricted peptides into the cytosol of target tumor cells for pMHCI presentation through the endogenous MHC-I antigen presentation pathway [12, 39].